MEIP vs. RDHL, MGTA, BYSI, LFVN, PWUP, CASI, ALVR, PMVP, TIL, and BCAB
Should you be buying MEI Pharma stock or one of its competitors? The main competitors of MEI Pharma include RedHill Biopharma (RDHL), Magenta Therapeutics (MGTA), BeyondSpring (BYSI), LifeVantage (LFVN), PowerUp Acquisition (PWUP), CASI Pharmaceuticals (CASI), AlloVir (ALVR), PMV Pharmaceuticals (PMVP), Instil Bio (TIL), and BioAtla (BCAB).
RedHill Biopharma (NASDAQ:RDHL) and MEI Pharma (NASDAQ:MEIP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.
In the previous week, MEI Pharma had 7 more articles in the media than RedHill Biopharma. MarketBeat recorded 12 mentions for MEI Pharma and 5 mentions for RedHill Biopharma. MEI Pharma's average media sentiment score of 0.37 beat RedHill Biopharma's score of -0.15 indicating that RedHill Biopharma is being referred to more favorably in the media.
RedHill Biopharma has higher earnings, but lower revenue than MEI Pharma.
MEI Pharma has a consensus price target of $7.00, indicating a potential upside of 96.63%. Given RedHill Biopharma's higher possible upside, analysts clearly believe MEI Pharma is more favorable than RedHill Biopharma.
RedHill Biopharma's return on equity of 48.32% beat MEI Pharma's return on equity.
7.2% of RedHill Biopharma shares are held by institutional investors. Comparatively, 52.4% of MEI Pharma shares are held by institutional investors. 6.8% of RedHill Biopharma shares are held by company insiders. Comparatively, 3.9% of MEI Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
RedHill Biopharma has a beta of 3.64, meaning that its share price is 264% more volatile than the S&P 500. Comparatively, MEI Pharma has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.
RedHill Biopharma received 42 more outperform votes than MEI Pharma when rated by MarketBeat users. Likewise, 67.99% of users gave RedHill Biopharma an outperform vote while only 61.11% of users gave MEI Pharma an outperform vote.
Summary
RedHill Biopharma beats MEI Pharma on 7 of the 13 factors compared between the two stocks.
Get MEI Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MEIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MEI Pharma Competitors List
Related Companies and Tools
